Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark S Freedman

Showing results (1-10 of 277) with videos related to

Pageof 28
Sort By:
Nature Reviews. Neurology|December 29, 2016
Multiple sclerosis: Is there a safe time to discontinue therapy in MS?Mark S Freedman
Neurology|January 6, 2011
Long-term follow-up of clinical trials of multiple sclerosis therapiesMark S Freedman
Neurology|January 6, 2011
Improving long-term follow-up studies of immunomodulatory therapiesMark S Freedman
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2009
'Time is brain' also in multiple sclerosisMark S Freedman
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2004
Primary progressive multiple sclerosis: cerebrospinal fluid considerationsMark S Freedman
Therapeutic Advances in Chronic Disease|September 3, 2013
Teriflunomide in relapsing multiple sclerosis: therapeutic utilityMark S Freedman
Continuum (Minneapolis, Minn.)|August 7, 2013
Present and emerging therapies for multiple sclerosisMark S Freedman
Nature Reviews. Neurology|June 4, 2014
Multiple sclerosis: Does aggressive MS warrant aggressive treatment?Mark S Freedman
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 4, 2008
Induction vs. escalation of therapy for relapsing multiple sclerosis: the evidenceMark S Freedman
Therapeutic Advances in Neurological Disorders|November 6, 2014
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndromeMark S Freedman
Pageof 28

Showing results (1-10 of 277) with videos related to

Sort By:
Pageof 28
Nature Reviews. Neurology|December 29, 2016
Multiple sclerosis: Is there a safe time to discontinue therapy in MS?Mark S Freedman
Neurology|January 6, 2011
Long-term follow-up of clinical trials of multiple sclerosis therapiesMark S Freedman
Neurology|January 6, 2011
Improving long-term follow-up studies of immunomodulatory therapiesMark S Freedman
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2009
'Time is brain' also in multiple sclerosisMark S Freedman
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2004
Primary progressive multiple sclerosis: cerebrospinal fluid considerationsMark S Freedman
Therapeutic Advances in Chronic Disease|September 3, 2013
Teriflunomide in relapsing multiple sclerosis: therapeutic utilityMark S Freedman
Continuum (Minneapolis, Minn.)|August 7, 2013
Present and emerging therapies for multiple sclerosisMark S Freedman
Nature Reviews. Neurology|June 4, 2014
Multiple sclerosis: Does aggressive MS warrant aggressive treatment?Mark S Freedman
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 4, 2008
Induction vs. escalation of therapy for relapsing multiple sclerosis: the evidenceMark S Freedman
Therapeutic Advances in Neurological Disorders|November 6, 2014
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndromeMark S Freedman
Pageof 28